If you have been following news on biotech or trials for cancer treatments lately, it is pretty hard to miss CEO Deborah Rathjen and Bionomics. Ms Rathjen has been taken from the lab to the boardroom and is turning this South Australian company into one of Australia's most noteworthy biotechs. They have clinical trials underway for an anti tumor drug and are commencing trials soon to develop a memory and anti-brain inflammation drug for Alzhemier’s sufferers. The next clinical trial they plan to work on is for anti-cancer compound BNC105. BNC105 has undergone a large phase II renal cancer trial in the US and Bionomics is awaiting approval for a first trial of the drug with ovarian cancer sufferers. They hope to eventually team up with large commercial partner so they can conduct further trials and market such a cancer drug.
To read more click here
To hear more from industry leaders from the biotech and pharmaceutical sector register for BioPharma Australasia which is on 23rd to the 24th August, 2012 at the Swissotel, Sydney.